Discovery of Potent Anti-Mpro Inhibitors for Covid-19 Treatment
Antivirals as effective as Remdesivir, blocking SARS-CoV-2 replication in vitro.
Researchers at Purdue University have discovered that a potent anti-Mpro inhibitor to be used to treat COVID-19. The anti-Mpro inhibitor is derived from Chloropyridyl ester derivatives. These inhibitors have shown that they have a strong antiviral potency against SARS-COV-2 in VERO cells. VERO cells are a lineage of cell cultures that have been derived from the kidneys of an African green monkey. This inhibitor can block COVID-19 in cell culture assay. This technology can be used to create COVID-19 vaccines. It can also be used in the treatment of COVID-19 patients so that it does not further affect them. This approach is just as effective as Remdesivir, a drug that has shown to help treat patients with COVID-19.
Potential Application:
-Treating Covid-19
-Preventing Covid-19
-Covid-19 Vaccines
Technology Validation: Tested in vero cells.
TRL: Chemistry and Chemical Analysis
Intellectual Property:
Provisional-Gov. Funding, 2020-04-10, United States
Provisional-Gov. Funding, 2020-12-01, United States
NATL-Patent, 2021-02-09, India
NATL-Patent, 2021-02-09, Japan
NATL-Patent, 2021-02-09, Republic of Korea
NATL-Patent, 2021-02-09, Canada
NATL-Patent, 2021-02-09, China
NATL-Patent, 2021-02-09, Europe
NATL-Patent, 2021-02-09, Mexico
NATL-Patent, 2021-02-09, Russia
Foreign, Non-PCT, 2021-02-09, Hong Kong
NATL-Patent, 2021-02-09, Brazil
PCT-Gov. Funding, 2021-02-09, WO
NATL-Patent, 2021-02-09, Australia
NATL-Patent, 2022-10-10, United States
Keywords: Chemistry and Chemical Analysis, Chloropyridyl Ester, Coronavirus, COVID-19, COVID-19 Treatment, Mpro Inhibitors, Vaccines, Vero Cells